Medtronic announces fda clearance and results of artificial intelligence algorithms for cardiac monitoring

Ai algorithms enhance linq ii™ insertable cardiac monitor diagnostic accuracy for improved management of patients dublin, july 28, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced u.s. food and drug administration (fda) clearance for two accurhythm™ ai algorithms for use with the linq ii™ insertable cardiac monitor (icm). accurhythm ai applies artificial intelligence (ai) to heart rhythm event data collected by linq ii, improving the accuracy of information physicians receive so they can better diagnose and treat abnormal heart rhythms.
MDT Ratings Summary
MDT Quant Ranking